Characterization of Fc-fusion protein aggregates derived from extracellular domain disulfide bond rearrangements

Journal of Pharmaceutical Sciences

Volumn 102, Issue 2, 2013, Pages 441-453

  Strand, James ^a   Huang, Chi Ting ^a   Xu, Jin ^b  

^a Acceleron Pharma   (United States)

^b University of Massachusetts Lowell   (United States)

Author keywords

Glycoprotein; Glycosylation; Protein aggregation; Protein folding refolding; Protein structure

Indexed keywords

ACTIVIN RECEPTOR LIKE KINASE 1; FC RECEPTOR; GLYCOSYLATED PROTEIN; HYBRID PROTEIN; MANNOSE; MONOMER; OLIGOMER; OLIGOSACCHARIDE; PROTEINASE;

ARTICLE; CARBOHYDRATE ANALYSIS; CIRCULAR DICHROISM; CONTROLLED STUDY; COVALENT BOND; DEGLYCOSYLATION; DISPERSION; DISULFIDE BOND; GEL PERMEATION CHROMATOGRAPHY; MASS SPECTROMETRY; MOLECULAR WEIGHT; PARTICLE SIZE; PEPTIDE MAPPING; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN AGGREGATION; PROTEIN DOMAIN; PROTEIN STRUCTURE; SIALYLATION;

EID: 84872497142     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23421     Document Type: Article

References (38)

1. Braun A, Kwee L, Labow MA, Alsenz J. 1997. Protein aggregates seem to play a key role among the parameters influencing the antigenicity of interferon alpha (IFN-α) in normal and transgenic mice. Pharm Res 14(10):1472-1478.
2. Carpenter JF, Randolph TW, Jiskoot W, Crommelin DJA, Middaugh CR, Winter G, Fan YX, Kirshner S, Verthelyi D, Kozlowski S, Clouse KA, Swann PG, Rosenberg A, Cherney B. 2009. Overlooking subvisible particles in therapeutic protein products: Gaps that may compromise product quality. J Pharm Sci 98(4):1201-1205.
3. Hermeling S, Crommelin DJ, Schellekens H, Jiskoot W. 2004. Structure-immunogenicity relationships of therapeutic proteins. Pharm Res 21(6):897-903.
4. Rosenberg AS. 2005. Effects of protein aggregates: An immunologic perspective. AAPS J 8(3):E501-E507.
5. Singh SK. 2010. Impact of product-related factors on immunogenicity of biotherapeutics. J Pharm Sci 100(2):354-387.
6. Kim YS, Randolph TW, Stevens FJ, Carpenter JF. 2002. Kinetics and energetics of assembly, nucleation, and growth of aggregates and fibrils for an amyloidogenic protein. J Biol Chem 30(277):27240-27246.
7. Cromwell MEM, Hilario E, Jacobsen F. 2006. Protein aggregation and bioprocessing. AAPS J 8(3):E572-E579.
8. Moore JMR, Patapoff TW, Cromwell MEM. 1999. Kinetics and thermodynamics of dimer formation and dissociation for a recombinant humanized monoclonal antibody to vascular endothelial growth factor. Biochemistry 38:13960-13967.
9. Lu HS, Chang WC, Mendiaz EA, Mann MB, Langley KE, Hsu YR. 1995. Spontaneous dissociation-association of monomers of the human-stem-cell-factor dimer. Biochem J 305(2):563-568.
10. Andya JD, Hsu CC, Shire SJ. 2003. Mechanisms of aggregate formation and carbohydrate excipient stabilization of lyophilized humanized monoclonal antibody formulations. AAPS Pharm Sci 5(2):E10.
11. Constantino HR, Langer R, Klibanov AM. 1994. Solid-phase aggregation of proteins under pharmaceutically relevant conditions. J Pharm Sci 83(12):1662-1669.
12. Ruf RAS, Lutz EA, Zigoneanu IG, Pielak GJ. 2008. Alpha-synuclein conformation affects its tyrosine-dependent oxidative aggregation. Biochemistry 47(51):13604-13609.
13. Philo JS, Arakawa T. 2009. Mechanisms of protein aggregation. Curr Pharm Biotech 10:348-351.
14. Schroder M, Schafer R, Friedl P. 2002. Induction of protein aggregation in an early secretory compartment by elevation of expression level. Biotech Bioeng 78(2):131-140.
15. Kueltzo LA, Wang W, Randolph TW, Carpenter JF. 2008. Effects of solution conditions, processing parameters, and container materials on aggregation of a monoclonal antibody during freeze-thawing. J Pharm Sci 97(5):1801-1812.
16. Chi EY, Sampathkumar K, Randolph TW, Carpenter JF. 2003. Physical stability of proteins in aqueous solution: Mechanisms and driving forces in non-native protein aggregation. Pharm Res 20(9):1325-1336.
17. Truehit MJ, Kosky AA, Brems DN. 2002. Inverse relationship of protein concentration and aggregation. Pharm Res 19(4):511-516.
18. Sahin E, Grillo AO, Perkins MD, Roberts CJ. 2010. Comparative effects of pH and ionic strength on protein-protein interactions, unfolding, and aggregation of IgG1 antibodies. J Pharm Sci 99(12):4830-4848.
19. Qian Y, Jing Y, Zheng JL. 2010. Glucocorticoid receptor-mediated reduction of IgG-fusion protein aggregation in Chinese hamster ovarian cells. Biotechnol Prog 26(5):1417-1423.
20. Van Buren N, Rehder D, Gadgil H, Matsumura M, Jacob J. 2008. Elucidation of two major aggregation pathways in an IgG2 antibody. J Pharm Sci 98(9):3013-3030.
21. Shukla AA, Gupta P, Han X. 2007. Protein aggregation kinetics during protein A chromatography. Case study for an Fc-fusion protein. J Chromatogr A 1171(1-2):22-28.
22. Fast JL, Cordes AA, Carpenter JF, Randolph TW. 2009. Physical instability of a therapeutic Fc fusion protein: Domain contributions to conformational and colloidal stability. Biochemistry 48:11724-11736.
23. Xu X, Didio DM, Leister KJ, Ghose S. 2010. Disaggregation of high-molecular weight species during downstream processing to recover functional monomer. Biotechnol Prog 26(3):717-726.
24. Van Maarschalkerweerd A, Wolbink GJ, Stapel SO, Jiskoot W, Hawe A. 2011. Comparison of analytical methods to detect instability of etanercept during thermal stress testing. Eur J Pharm Biopharm 78:213-221.
25. Mitchell D, Pobre EG, Mulivor AW, Grinberg AV, Castonguay R, Monnell TE, Solban N, Ucran JA, Pearsall RS, Underwood KW, Seehra J, Kumar R. 2010. ALK1-Fc inhibits multiple mediators of angiogenesis and suppresses tumor growth. Mol Cancer Ther 9(2):379-388.
26. Li Y, Weiss WF, Roberts CJ. 2009. Characterization of high-molecular-weight nonnative aggregates and aggregation kinetics by size-exclusion chromatography with inline multi-angle laser light scattering. J Pharm Sci 98(11):3997-4016.
27. Cooper CA, Gasteiger E, Packer N. 2001. GlycoMod-A software tool for determining glycosylation compositions from mass spectrometric data. Proteomics 1:340-349.
28. Kornfeld R, Kornfeld S. 1985. Assembly of aspargine-linked oligosaccharaides. Ann Rev Biochem 54:631-664.
29. Hawe A, Kasper JC, Friess W, Jiskoot W. 2009. Structural properties of monoclonal antibody aggregates induced by freeze-thawing and thermal stress. Eur J Phram Sci 38(2):79-87.
30. Pawel-Rammingen U, Johansson BP, Bjorck L 2002. IdeS, a novel streptococcal cysteine proteinase with unique specificity for immunoglobulin G. EMBO J 21(7):1607-1615.
31. Wang C, Eufemi M, Turano C, Giartosio A. 1996. Influence of the carbohydrate moiety on the stability of glycoproteins. Biochemistry 35(23):7299-7307.
32. Mer G, Hietter H, Lefevre JF. 1996. Stabilization of proteins by glycosylation examined by NMR analysis of a fucosylated proteinase inhibitor. Nat Struct Biol 3(1):45-53.
33. Gervais V, Zerial A, Oschkinat H. 1997. NMR investigations of the role of the sugar moiety in glycosylated recombinant human granulocyte-colony-stimulating factor. Eur J Biochem 247:386-395.
34. Roberts CJ. 2007. Non-native protein aggregation kinetics. Biotechnol Bioeng 98(5):927-938.
35. Morris AM, Watzky MA, Finke RG. 2009. Protein aggregation kinetics, mechanism, and curve-fitting-A review of the literature. Biochim Biophys Acta 1794(3):375-397.
36. Frand AR, Cuozzo JW, Kaiser CA. 2000. Pathways for protein disulfide bond formation. Trends Cell Biol 10(5):203-210.
37. Zhang W, Czupryn MJ. 2002. Free sulfhydryl in recombinant monoclonal antibodies. Biotechnol Prog 18(3):509-513.
38. Remmele RL, Callahan WJ, Krishnan S, Zhou L, Bondarenko PV, Nichols AC, Kleemann GR, Pipes GD, Park S, Fodor, Kras E, Brems DN. 2006. Active dimer of epratuzumab provides insight into the complex nature of an antibody aggregate. J Pharm Sci 95(1):126-145.